Search
All Clinical Trials
A listing of 23118 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
493 - 504 of 23118
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Recruiting
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/16/2025
Locations: Clinical Trial Site, Iowa City, Iowa +6 locations
Conditions: Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Recruiting
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/16/2025
Locations: University Of Miami, Miami, Florida +15 locations
Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Change in MAPSE During Treatment of Sepsis
Recruiting
Patients with bloodstream infections (sepsis) have been found in prior studies to have infection-related heart dysfunction, even if they did not have preexisting heart problems. Factors related to the infection may cause the heart to not pump as well as it should, causing critical illness in the form of low blood pressure (shock) and heart failure. Ultrasound is frequently used in the emergency department to evaluate why a patient might have low blood pressure. Part of that evaluation may includ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Sepsis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Recruiting
The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/16/2025
Locations: Allervie Clinical Research, Birmingham, Alabama +83 locations
Conditions: Moderate to Severe Asthma
Longitudinal Outpatient Treatment for Cannabis Use Disorder
Recruiting
This study is a placebo-controlled randomized trial comparing the effects of hemp-derived cannabidiol (CBD) with and without Delta-9-tetrahydrocannabinol (THC), relative to placebo, on reducing cannabis use and cannabis use disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. Participants enroll in the study for 8 weeks (with telehealth follow-ups at 12 and 16 weeks) and are randomized to either full spectrum CBD, broad spectrum CBD, or placebo. Participants ar... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/16/2025
Locations: University of Colorado Boulder, Boulder, Colorado
Conditions: Cannabis Use Disorder
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Recruiting
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/16/2025
Locations: Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, California +40 locations
Conditions: Advanced Melanoma
Evaluating Intuitive 3D Models in Preoperative Surgical Planning for Thoracic and Colorectal Procedures.
Recruiting
The Study Objective: To evaluate the clinical utility of a 3D model with 2D CT/MRI scans during simulated preoperative surgical planning of open, laparoscopic, or robotic-assisted anatomic lung resection (segmentectomy, lobectomy) or Lower Anterior Resection (LAR) procedures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana +3 locations
Conditions: Thoracic, Colorectal Disorders
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Recruiting
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: HonorHealth Research Insisute, Scottsdale, Arizona +18 locations
Conditions: Metastatic Uveal Melanoma
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Recruiting
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Beverly Hills Cancer Center, Beverly Hills, California +13 locations
Conditions: Hepatocellular Carcinoma
Reimagining Interventions for Support and Education in Hypersensitivity Pneumonitis
Recruiting
The central hypothesis is that a peer coach-delivered intervention that includes cognitive behavioral principles combined with theory-driven patient education will improve health-related quality of life (HRQOL) of patients with hypersensitivity pneumonitis (HP). The goal of this behavioral and educational intervention, RISE-HP, is to improve health-related quality of life in people who have hypersensitivity pneumonitis and assess feasibility and accessibility of this intervention.
Patients with... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/16/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Hypersensitivity Pneumonitis
A Study of LY4268989 (MORF-057) in Healthy Participants
Recruiting
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/16/2025
Locations: CenExel ACT, Anaheim, California
Conditions: Healthy
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Recruiting
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class of drugs that antagonize some specific cell receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/15/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
493 - 504 of 23118